Drug maker Moderna has just announced encouraging interim results from the ongoing phase 1 trial for its experimental coronavirus vaccine. The early results suggest the vaccine has the potential to confer immunity against covid-19 in people.
What is Moderna coronavirus vaccine and how does it work?
Moderna specializes in vaccines designed to elicit an immune response against the coronavirus through the virus’s mRNA—genetic instructions for the virus to replicate inside the host. New methods like Moderna’s are fast to prepare, but they have never led to a licensed vaccine for sale.
Phase 1 trials
The purpose of a phase 1 clinical trial is to establish whether or not the drug or vaccine being investigated is safe. It’s not designed to test for efficacy. That being said, the trials can still provide some insights into the potential of the drug or vaccine to treat patients. Moderna’s trial, which began in March and is still ongoing, is set to enroll up to 105 people. Each participant receives either two shots at 25 micrograms or 100 micrograms (about four weeks apart) or a single dose at 250 micrograms.
The new results
Moderna released antibody data for eight participants (aged 18 to 55), four in the 25-microgram arm and four in the 100-microgram arm. The results, according to the company, show that 25-microgram participants developed neutralizing antibodies to the coronavirus at levels comparable to recovered covid-19 patients; those in the 100-microgram arm had antibody levels that “significantly exceeded” the level in recovered patients. Adverse effects have been observed, but the company’s statement insists they “have been transient and self-resolving.”
Next steps
The results are encouraging, but we can’t draw conclusions from a phase 1 trial, with data from only eight participants so far. Way more data is needed. The FDA has already given Moderna approval for a phase 2 trial (testing the drug’s biological effect on patients), and Moderna says it will add a 50-microgram arm to the phase 2 study. A phase 3 trial is expected to start in July. According to the Wall Street Journal, if all Moderna’s trials go well—and that’s a big if—the FDA could grant emergency-use authorization for the vaccine by the fall.
Other companies with potential vaccines
Another U.S. biotech company, Novavax, is starting trials for its vaccine candidate and is confident of producing 100m doses by end of 2020.
Japanese biotech company, Takara Bio Inc is also commencing trials with production facilities ready. Takara partnered with bio company AnGes and Osaka University to develop the DNA COVID-19 vaccine.